(ŎɫĨƟĨůƳŎýŤ (ĨƳĨĚƳŎŸů Ÿŀ ª ¢ª့!ŸÖ့ ÖýƟŎýůƳ oƼƳýƳŎŸůƧ


ªŎŬƛŤĨǙý™ ª ¢ª့!ŸÖ့ ÖýƟŎýůƳƧ (ŎƟĨĚƳ Ё¢¿{Ђ*


• 57 3&5 DVVD\ WR DOORZ LQ YLWUR TXDOLWDWLYH DQG GLHUHQWLDO detection of the SARS-CoV-2 variant mutations N501Y, E484K, E484Q, and L452R:


These mutations are present in potential variants of interest LQFOXGLQJ WKRVH WKDW ZHUH UVW LGHQWLHG LQ WKH 8QLWHG .LQJGRP (B.1.1.7), South Africa (B.1.351), Brazil/Japan (P.1 and P.2), New York (B.1.526/B.1.526.1), California (B.1.427/B.1.429), Nigeria (B.1.525) and India (B.1.617/B.1.617.1/B.1.617.2/B.1.617.3).


• 6LPSOH ZRUNRZ GLUHFW IURP VDPSOH ZLWK QR H[WUDFWLRQ RT-PCR assay direct from nasopharyngeal and nasal swab specimens with no RNA extraction needed. Reagents are pre- aliquoted and are immediately ready for use.


• Leverages unLTXH XRUHVFHQFH PHOWLQJ FXUYH DQDO\VLV IHDWXUH of the LIAISON®


MDX:


)OXRUHVFHQW SUREHV VSHFLF IRU HDFK PXWDWLRQ DUH XVHG WR SHUIRUP D SRVW DPSOLFDWLRQ PHOWLQJ DQDO\VLV WR TXLFNO\ GLHUHQWLDWH DQG visualize between wild type & mutant target regions.


Learn More SCV2PA0621


www.molecular.diasorin.com +1 (562) 240-6500


*For Research Use Only. Not for use in diagnostic procedures.


Simplexa, LIAISON MDX, and the associated logos are all trademarks or registered WUDGHPDUNV RI 'LD6RULQ 0ROHFXODU //& RU LWV DɝOLDWH LQ WKH 8 6 DQG RU RWKHU countries.


The quality of treatment starts with diagnosis.

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44